SBL
DMK

Sargent Bickham Lagudis’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sargent Bickham Lagudis’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-67
Closed -$16 – 757
2016
Q3 		$16 Hold
67
– – ﹤0.01% 505
2016
Q2 		$13K Hold
67
– – ﹤0.01% 516
2016
Q1 		$29K Buy
+67
New +$23.9K ﹤0.01% 436

Other funds holding DMK

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SGS
Sterling Global Strategies Carlsbad, California $18M AUM 11.58% 1-Year Est. Return

Sargent Bickham Lagudis's DMK Position: Q4 2016 in Review

Sargent Bickham Lagudis sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2016, closing a stake of 67 shares — an estimated $16 sold.

Sargent Bickham Lagudis first reported a position in DMK in Q1 2016 and held it in 3 quarters. The position peaked at $29K in Q1 2016. 35 funds tracked by Wall St. Rank hold DMK as of Q4 2016.

  • Sargent Bickham Lagudis reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2016 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 67 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2016, an estimated $16.
  • Sargent Bickham Lagudis first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2016 and held it in 3 quarters.
  • Sargent Bickham Lagudis's DMK Pharmaceuticals Corporation Common Stock position peaked at $29K in Q1 2016.
  • 35 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2016.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2016, filed 13 Sep 2021.